Storing AOD-9604: Best Practices
16 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: February 2026
Lyophilized Peptide (Unopened)
Lyophilized AOD-9604 powder is stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) in a sealed, desiccated container. Avoid direct light exposure.
Reconstituted Peptide
Reconstitute with Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for injection. Once reconstituted, store at 2°C to 8°C (36°F–46°F) and use within 14–21 days. Do not freeze reconstituted solution.
Handling Precautions
- Allow vial to reach room temperature before opening to prevent condensation.
- Do not shake vigorously; swirl gently during reconstitution.
- Use aseptic technique for all preparations.
- Discard any solution that appears cloudy or contains particulate matter.
Editorial Research Note
“In Zucker (fa/fa) rats, oral administration at 200–600 µg/kg/day for 18 days showed dose-dependent fat-mass reduction with preservation of lean body mass [8].”
References
- Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182-5189.
- Ng, F. M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.
- Ng, F. M. & Bornstein, J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol, 235(1), E55-E59.
- Ng, F. M., et al. (2000). Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol, 25(3), 287-298.
- Kwon, D. R. & Park, G. Y. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci, 45(4), 426-432.
- Lateral Pharma Pty Ltd. (2020). LAT8881 (AOD9604) host-protective experimental protocol for influenza A virus infection. Clinical development update.
- Heffernan, M., et al. (2000). The effects of AOD9604 on beta-3 adrenergic receptor expression and lipolysis in obese mice. Obesity Research, 8(S1) [conference abstract; not indexed]. Peer-reviewed full report: Heffernan M, et al. Endocrinology. 2001;142(12):5182-9.
- Groenewegen, W. A., et al. (2004). Oral AOD9604 reduces body fat in Zucker rats by selective fat mass reduction without effect on lean body mass. Appetite, 42(3), abstract.
- Ng, F. M. & Roupas, P. (1999). Anti-lipogenic action of the C-terminal fragment 177-191 of human growth hormone. Res Commun Mol Pathol Pharmacol, 106(1-2), 35-48.
- Lobie, P. E. (1999). Signal Transduction Through the Growth Hormone Receptor. In: Endocrine Updates. Springer US.
- Stier, H., et al. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab, 3(1-2), 7-15.
- Metabolic Pharmaceuticals Limited. (2007). Metabolic’s obesity compound – Phase 2B clinical trial results. ASX Announcement, 27 June 2007.
- Thompson, G., et al. (2004). Phase 2b clinical trial results for AOD9604. Presented at the International Congress on Obesity.
- Stier, H. & Kenley, D. (2012). Preclinical and clinical safety review of AOD9604. Regul Toxicol Pharmacol, 64(2), S34-S35 [conference abstract; not indexed in PubMed or CrossRef]. Peer-reviewed full report: Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15.
- U.S. Food and Drug Administration. (2023). Bulk Drug Substances Used in Compounding Under Section 503B. FDA.gov.
- World Anti-Doping Agency. (2024). The Prohibited List: International Standard. Section S2.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
View Full AOD-9604 Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.